Mauna Kea Technologies will host a webinar on July 21, 2026, to review its business performance for the first half of 2026. The event aims to provide shareholders and the financial community with insights into the company's operational highlights during this period.

Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer, will deliver live commentary on the key developments. The session will include a question-and-answer segment to address investor queries.

Webinar Details

The webinar is scheduled for Tuesday, July 21, 2026. Participation requires advance registration. A replay of the session will be made available for those who register.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company specializing in the manufacture and sale of Cellvizio. This platform is a multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) system designed for real-time in vivo cellular imaging. The technology assists physicians in monitoring disease progression, assessing real-time reactions, classifying indeterminate areas, and guiding surgical interventions across various medical specialties.

Mauna Kea Technologies has established a shareholder loan agreement with Vester Finance to secure additional funding for commercial growth and development opportunities. The optional financing facility provides up to €4.0 million, available over a period of 24 months, and is repayable in cash or new shares. This arrangement is intended to strengthen the company's momentum in the United States and internationally while supporting geographic expansion into new strategic territories following entries into Switzerland, the United Kingdom, the United Arab Emirates, and Turkey in the first half of 2026.

As of the date of the announcement, no advance has been drawn under the agreement. The company retains the discretion to mobilize the liquidity line based on its needs, with no contractual obligation to draw funds. Current financial visibility extends into the second quarter of 2027 without utilizing this advance or exercising warrants from the November 2025 capital increase.

Principal terms of the loan

Under the agreements dated July 15, 2026, Vester Finance has committed to granting a shareholder loan with a maximum principal amount of €4.0 million. The company may request advances of up to €0.5 million each. If repaid in cash, the advances bear interest at a rate of 7.0% per year from the date of payment and mature on January 15, 2029. The company retains the right to suspend or terminate the agreement at any time without cost.

In the event of repayment in shares, new shares would be issued based on the average stock market price preceding each issuance, with a maximum discount of 5%. The issuance is capped at 24,000,000 new shares, representing at most 12.3% of the current share capital. Assuming full repayment in shares, Vester Finance would hold approximately 21.6% of the company’s share capital on a non-diluted basis and 15.1% on a diluted basis.

Governance and regulatory approval

The transaction was authorized under the 14th resolution of the Combined General Meeting of June 4, 2026, and approved by the company's Board of Directors. It does not require a prospectus approval by the Autorité des marchés financiers (AMF). The number of shares issued under this arrangement will be disclosed in the monthly report on shares and voting rights published on the company's website.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated that the arrangement provides valuable financial flexibility to accelerate the commercial adoption of Cellvizio®. The company plans to selectively strengthen its U.S. commercial force and expand the international presence of CellTolerance® using these resources.